Vascular Disrupting Agents Market Size, Share & Trends Analysis Report By Indication, By Therapeutic Area (Hematological Malignancies, Solid Tumors), By Product, By Molecule, By Therapy, By Route of Administration, By Region, And By Segment Forecasts, 2029-2034.
Segmentation of Vascular Disrupting Agents Market
Global Vascular Disrupting Agents Market, by Indications, 2020-2030 (Valu US$ Mn)
- Chemotherapy-Induced Neutropenia
- Glioblastoma
- Liver Cancer
- Mesothelioma
- Non-Small Cell Lung Cancer
- Prostate Cancer
- Ovarian Cancer
- Renal Pelvis
- Ureter Cancer
Global Vascular Disrupting Agents Market, by Therapeutic Area, 2020-2030 (Valu US$ Mn)
- Hematological Malignancies
- Solid Tumors
Global Vascular Disrupting Agents Market, by Molecules, 2020-2030 (Value US$ Mn)
- Tubulin Binding Agents
- Flavonoids
- Ligand-Directed Agents
Global Vascular Disrupting Agents Market, by Therapy, 2020-2030 (Valu US$ Mn)
- Mono
- Combination
Global Vascular Disrupting Agents Market, by Route of Administration, 2020-2030 (Value US$ Mn)
- Oral
- Intravenous
Global Vascular Disrupting Agents Market, by Product, 2020-2030 (Valu US$ Mn)
- Bavituximab
- Icaritin
- NGR-TNF
- Padeliporfin
- Plinabulin
- VB-111
- Others
Global Vascular Disrupting Agents Market, by Region, 2020-2030 (Value US$ Mn)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
North America Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)
- U.S.
- Canada
Europe Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Landscape
- Company Overview
- Financial Performance
- Key Development
- Latest Strategic Developments
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Vascular Disrupting Agents Market Snapshot
Chapter 4. Global Vascular Disrupting Agents Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Indication, Estimates & Trend Analysis
5.1. By Indications, & Market Share, 2029 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Indications:
5.2.1. Chemotherapy-Induced Neutropenia
5.2.2. Glioblastoma
5.2.3. Liver Cancer
5.2.4. Mesothelioma
5.2.5. Non-Small Cell Lung Cancer
5.2.6. Prostate Cancer
5.2.7. Ovarian Cancer
5.2.8. Renal Pelvis
5.2.9. Ureter Cancer
Chapter 6. Market Segmentation 2: By Therapeutic Area Estimates & Trend Analysis
6.1. By Therapeutic Area & Market Share, 2029 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Therapeutic Area:
6.2.1. Hematological Malignancies
6.2.2. Solid Tumors
Chapter 7. Market Segmentation 3: By Molecule Estimates & Trend Analysis
7.1. By Molecule & Market Share, 2029 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Molecule:
7.2.1. Tubulin Binding Agents
7.2.2. Flavonoids
7.2.3. Ligand-Directed Agents
Chapter 8. Market Segmentation 4: By Therapy Estimates & Trend Analysis
8.1. By Therapy & Market Share, 2029 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Therapy
8.2.1. Mono
8.2.2. Combination
Chapter 9. Market Segmentation 5: By Route of Administrations Estimates & Trend Analysis
9.1. By Route of Administrations & Market Share, 2029 & 2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Route of Administrations:
9.2.1. Oral
9.2.2. Intravenous
Chapter 10. Market Segmentation 6: By Products Estimates & Trend Analysis
10.1. By Products & Market Share, 2029 & 2034
10.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:
10.2.1. Bavituximab
10.2.2. Icaritin
10.2.3. NGR-TNF
10.2.4. Padeliporfin
10.2.5. Plinabulin
10.2.6. VB-111
10.2.7. Other Products
Chapter 11. Vascular Disrupting Agents Market Segmentation 7: Regional Estimates & Trend Analysis
11.1. North America
11.1.1. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts By Indications, 2021-2034
11.1.2. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2021-2034
11.1.3. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts By Molecule, 2021-2034
11.1.4. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Therapy, 2021-2034
11.1.5. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
11.1.6. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Products, 2021-2034
11.1.7. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
11.2. Europe
11.2.1. Europe Vascular Disrupting Agents Market revenue (US$ Million) By Indications, 2021-2034
11.2.2. Europe Vascular Disrupting Agents Market revenue (US$ Million) By Therapeutic Area, 2021-2034
11.2.3. Europe Vascular Disrupting Agents Market revenue (US$ Million) By Molecule, 2021-2034
11.2.4. Europe Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Therapy, 2021-2034
11.2.5. Europe Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
11.2.6. Europe Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Products, 2021-2034
11.2.7. Europe Vascular Disrupting Agents Market revenue (US$ Million) by country, 2021-2034
11.3. Asia Pacific
11.3.1. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) By Indications, 2021-2034
11.3.2. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) By Therapeutic Area, 2021-2034
11.3.3. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) By Molecule, 2021-2034
11.3.4. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Therapy, 2021-2034
11.3.5. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
11.3.6. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Products, 2021-2034
11.3.7. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) by country, 2021-2034
11.4. Latin America
11.4.1. Latin America Vascular Disrupting Agents Market revenue (US$ Million) By Indications, (US$ Million) 2021-2034
11.4.2. Latin America Vascular Disrupting Agents Market revenue (US$ Million) By Therapeutic Area, (US$ Million) 2021-2034
11.4.3. Latin America Vascular Disrupting Agents Market revenue (US$ Million) By Molecule, (US$ Million) 2021-2034
11.4.4. Latin America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Therapy, 2021-2034
11.4.5. Latin America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
11.4.6. Latin America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Products, 2021-2034
11.4.7. Latin America Vascular Disrupting Agents Market revenue (US$ Million) by country, 2021-2034
11.5. Middle East & Africa
11.5.1. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) By Indications, (US$ Million) 2021-2034
11.5.2. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) By Therapeutic Area, (US$ Million) 2021-2034
11.5.3. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) By Molecule, (US$ Million) 2021-2034
11.5.4. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Therapy, 2021-2034
11.5.5. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034
11.5.6. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Products, 2021-2034
11.5.7. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) by country, 2021-2034
Chapter 12. Competitive Landscape
12.1. Major Mergers and Acquisitions/Strategic Alliances
12.2. Company Profiles
12.2.1. AGC Biologics
12.2.2. Avid Bioservices
12.2.3. Bionomics
12.2.4. Beijing Shenogen Biomedical
12.2.5. Mateon Therapeutics
12.2.6. Myrexis
12.2.7. VBL Therapeutics
12.2.8. Steba biotech
12.2.9. BeyondSpring Pharmaceuticals
12.2.10. Immune Pharmaceuticals
12.2.11. Nereus Pharmaceuticals
12.2.12. Madrigal Pharmaceuticals, Inc.
12.2.13. Celgene Corporation
12.2.14. Bionomics Ltd.
12.2.15. Lees Pharmaceutical Holdings.
12.2.16. Other Prominent Players
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
AGC Biologics (Denmark), Avid Bioservices (US), Bionomics (Australia), Beijing Shenogen Biomedical (China), Mateon Therapeutics (US), Myrexis (US), VB
The Vascular Disrupting Agents Market is expected to grow at a 10% CAGR during the forecast period for 2029-2034.
Indications, therapeutic area, molecules, therapy, route of administration, and product are the key segments of the Vascular Disrupting Agents Market
North American region is leading the Vascular Disrupting Agents Market.